Initial thoughts on the full results of the ELEVATE TN study of AstraZeneca PLC’s Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), administered alone or with the anti-CD20 MAb, obinutuzumab (Roche/Genentech Inc.’s Gazyva), as first-line therapy for chronic lymphocytic leukemia, have alighted on Calquence’s favorable tolerability profile, and the intense competitive pressure likely to arise in the therapeutic segment from a number of BTK inhibitors currently in development.
AstraZeneca's Calquence Steps Up in First-Line CLL
Full Results Of First-Line Calquence Use In CLL
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.
More from Anticancer
• By
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.